Muhammad Aqib Faizan: The Role of Novel Anticoagulants Factor XI/XIa Inhibitors in the Atrial Fibrillation Population
Muhammad Aqib Faizan, Clinical Intern at District Headquarter Hospital, MTI, DIKhan, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:
”New study
I had the privilege of leading this study regarding the role of novel anticoagulants FactorXI/XIa inhibitors in atrial fibrillation population (high-thromboembolic-risk patients (mean CHA2DS2-VASc scores 3.9-5.0).
The findings offer a compelling trade-off.
- Significantly lower risk of bleeding across all doses
- Fourfold rise in ischemic stroke
- No significant difference in cardiovascular death, all-cause mortality, or major adverse events indicates general tolerance and neutrality in survival outcomes.
This profile may offer a lifeline for high-risk patients-those in whom bleeding concerns limit traditional anticoagulation.
But the fourfold increase in ischemic stroke is a critical signal.
Proud of what this team accomplished. Huge thanks to Tooba Rehman, Zeyad Kholeif, Fatima Saeed, Jibran Ikram, Alina Tanvir, Carlos Alberto E., Saad Ahmed Waqas, and our mentor, Luis Cerna, whose insights made this happen.”
Title: Dose-Response Efficacy and Safety of Factor XI/XIa Inhibitors in Atrial Fibrillation; a Systematic Review and Meta-Analysis With Subgroup Exploration and Trial Sequential Validation
Authors: Muhammad Aqib Faizan, Tooba Rehman, Mrunalini Dandamudi, Jaivardhan A. Menon, Victoria Zecchin Ferrara, Zeyad Kholeif, Alina Tanvir, Fatima Saeed, Jibran Ikram, Moiuz Chaudhri, Carlos Espiche, Main Muhammad Salman Aslam, Zainab Humayun, Ahmad Mustafa Khalid, Saad Ahmad Waqas, Raheel Ahmad, Luis Cerna
Read the Full Article on Clinical Cardiology.
Stay updated with Hemostasis Today.
-
Aug 21, 2026, 14:32Kenneth Nollet: Building the Future of Transfusion Laboratory Science
-
Aug 21, 2026, 14:14Tareq Abadl: A Positive Antibody Screen is Not The Diagnosis
-
Aug 21, 2026, 14:08Katrina Snow։ Transfusion Trends and Quality Improvement in Sickle Cell Disease
-
Aug 21, 2026, 14:00Rucha Patil: The Power of Point-of-Care Testing in Hemostasis
-
Aug 21, 2026, 13:56Sarah Kowalski։ Supporting the Next Generation of Transfusion Laboratory Scientists
-
Aug 21, 2026, 13:51Join EHC 2026 Annual Conference
-
Aug 21, 2026, 12:57David McIntosh: Why Do Blood Supplies Still Fall Short?
-
Aug 21, 2026, 12:48Joshua Penrod: 35 Years of Progress in Plasma Safety
-
Aug 21, 2026, 12:42Moustafa Abdou: Diagnosis and Management of Pyruvate Kinase Deficiency